When Wei-Wu He WG99 was a college student at Nanjing University in the 1980s, he studied under a modern Methuselah. At 85, biochemist Zheng Ji had already lived through an astounding amount of history. “He went through the Qing dynasty’s collapse, the warlord years, World War I, World War II, the Chinese Civil War, the founding of the People’s Republic — he was even arrested for a while during the Cultural Revolution,” Zheng’s former student explains. “He always said he wanted to live past 100 just to show people the potential.”
Zheng may have surpassed even his own expectations, publishing a book about longevity at age 108 and considered to be the oldest living professor before his death at 110. This is the kind of life that He imagines for himself — and for me, and for you too. Not just a long life, but one of lasting mental acuity and fulfillment.
Since 2019, He, an investor, a biochemist, and a serial entrepreneur, has worked as chairman and CEO of Human Longevity, a health intelligence company combining AI, genomics, and imaging to extend the human lifespan. He has furthered his mission by partnering with Wharton’s Health Care Excellence and Leadership Strategy (HEALS) Initiative, which is researching how to ready the business world for longer lives, among other topics.
I met with He on a typical overcast Bay Area day at the Human Longevity offices in South San Francisco. Inside, I passed a humming full-body MRI machine, an echocardiogram room, a blood-draw area, and a bone-density scanner. Though a number of clients were getting tested that day, they were tucked into private rooms. The office was clean and minimalistic, with warm lighting, much like how one might imagine a spa aboard a spaceship.
I landed in a room that looked more like a hotel suite than a medical office, with comfortable couches, a side table lined with snacks, and a full bathroom with a shower. This space was designed with a specific type of client in mind: executives flying into town, taking a short car ride to Human Longevity, getting their tests done, and freshening up before meeting business contacts nearby.
Tall and wearing a navy suit, He entered the room with a broad smile stretched across his face. Bill Snider W91 WG99, partner at BroadOak Capital and board member at various bioscience firms, had told me what to expect from his former classmate: “His mind works very quickly. You’re going to get a full dose of it when you meet him.” Indeed, He came across as animated and engaged. He cites data points off the top of his head and enjoys a wide-ranging conversation. By the time we meet at 10:30, he has already taken several other meetings, including one with a German influencer and another with potential partners for launching Human Longevity in Saudi Arabia. After that, he spent 40 minutes in his Tesla, primarily on autopilot, to get to the office. Despite his packed schedule, he shows no sign of flagging energy. Talking about the potential of genetic testing and extending the human lifespan only fires him up.
“Genetics is your destiny,” He tells me with a mischievous grin. “But you can alter your destiny.”
He, who was raised in Wuxi, China, likes to say that his interest in longevity was more than five decades in the making. His mother worked as a professor of organic chemistry, and his father ran a state-owned company. He was still a young boy during the Cultural Revolution, when his parents were sent to the countryside to live in rural labor camps. Though today, with modern roads, they were only a 30-minute car ride away, in the 1970s the family was separated by a four-hour bus trip. He only saw his parents once or twice a year. “My grandmother was my surrogate mother,” he says.
Then in her 60s, his grandmother was loving and vivacious. She also seemed incredibly healthy — until she was diagnosed with late-stage cervical cancer. Within a month, she died. The loss devastated He. “I was always interested in why somebody as healthy as my grandmother could suddenly die,” he says. Her passing became the emotional engine that would power his career.
He was fascinated by medicine and studied biochemistry at Nanjing University, in China’s equivalent of the Ivy League. There, he became a student of Professor Zheng, who was studying longevity. Zheng taught that there were two pillars of longevity: metabolic balance and emotional balance. The first was impacted by food, exercise, and sleep. The second relied on reducing stress and finding inner peace.

With his mentor’s support, He applied to a Carter administration program that admitted top Chinese students to the U.S. and arrived in Texas for his PhD in molecular biology from Baylor College of Medicine with just $50 in his pocket. There, he cloned his first gene, the prostate-specific antigen, and researched prostate cancer. He went on to the Mayo Clinic and then Massachusetts General Hospital. By 26, He had been set up for a successful career in academia, but when offered his dream job — an assistant professorship at Harvard — he turned it down. He had encountered the next revolutionary character who would change his life.
In 1992, genomics researcher Craig Venter had been working to sequence the whole human genome with the Human Genome Project under the National Institutes of Health. Venter had already emerged as a maverick, with his genome sequencing methods drawing skepticism and even some hostility from the scientific establishment. “Everybody was against him,” He explains. “People thought he was crazy.” But after reading one of Venter’s papers, He was fascinated by his thinking. Three weeks later, he got a call: Venter had left the Human Genome Project and built a new company — and was looking for a scientist who knew how to clone genes.
Human Genome Sciences would be among the first industrialized DNA-sequencing platforms. “It was mind-boggling,” He says. “They’d already bought 100 sequencing machines. I cloned one gene and got my PhD. They were sequencing thousands of genes at industrial scale.” Venter grew the company quickly. Working under him, He realized the potential for startups to push progress. “Can you imagine Elon Musk building Tesla inside General Motors or Ford?” He says. “By forming a new company, you have a brand-new business plan, and you raise money from people who actually believe in your mission.”
Human Genome Sciences went public in 1993 and hit a $2 billion valuation in 1996. He made his first million dollars and decided to use the money to create his next big opportunity: OriGene Technologies, which developed research tools for life sciences and clinical diagnostics. Hungry to learn more about business leadership, He began the Wharton Executive MBA program in 1997.
Thanks to Wharton’s creation of cohorts based on geography, He, who lived in a suburb of Washington, D.C., met Snider, a classmate in Baltimore. Snider came from the finance world and was working in fixed income marketing, managing mutual funds, and on trading desks. The two became fast friends — and realized they could seize a unique opportunity. Maryland was one of the largest economies for the biotech industry but had a dearth of venture capital firms. “So we started one,” Snider says.
They had complementary backgrounds. “Bill knows how to manage money, and I’m the crazy scientist,” He says with a laugh. But Wharton gave him the expertise he was missing. “Before I got my Wharton degree, people always said, ‘You don’t understand finance, marketing, any of that,’” he tells me. “After I got the degree, nobody questioned it anymore.” Manny Friedman, a Wharton guest speaker who ran D.C.’s only big investment banking firm at the time, helped raise capital for Emerging Technology Partners, a life-sciences VC fund. With that backing, He hit the ground running. “He’s a force of nature,” Snider says. “We had a lot of fun together. He’s a really creative thinker with a lot of energy.”

In total, He has founded and funded more than 100 biotech companies, authored more than 90 publications, and holds more than 30 patents. He has also built businesses in China, including Genetron Health, a precision oncology platform. “Telling him no really isn’t an obstacle at all in his perspective,” Snider says. “That’s your answer for now, but eventually, he’ll change it.” When asked about his relentless drive, He laughs. “There’s probably a genetic element to it — I’m always trying to win,” he admits. “It’s in my blood. I don’t take defeat as an answer.”
Which, perhaps, makes him the perfect person to tackle the problem of death and dying.
The human longevity industry has boomed since the 2020 pandemic, and with advances in AI, it only shows signs of more growth. Some forecasts suggest the market could balloon to $67 billion by 2035. Jeff Bezos and Sam Altman are among the tech titans who have staked fortunes on companies like Altos Labs and Retro Biosciences, which are trying to reprogram aging at the cellular level. But the rush to find a fountain of youth has also drawn hype and skepticism. Entrepreneur Bryan Johnson, for instance, has become infamous for spending millions of dollars, downing hundreds of pills, and even receiving blood plasma infusions from his teenage son in pursuit of eternal life. Johnson sat on Human Longevity’s board before departing about 10 years ago for other ventures. Among them: selling a brand of extra-virgin olive oil for “longevity,” marketed under the name “Snake Oil.”
For every peer-reviewed advance in genomics or milestone in early cancer detection, there’s an influencer hawking a miracle supplement or pseudoscientific health hack. He is blunt about the problem: The term longevity has been misused. “Longevity means scientific longevity,” He says. “It’s about using data, using technology.”
That distinction is critical for an industry that is literally about life and death. As much as the tech world’s leaders have invested in improving their health, plenty of executives have died too soon from disease. Apple’s Steve Jobs died of pancreatic cancer in 2011. His was a treatable form of cancer, but he delayed recommended medical intervention in favor of alternative medicine. Susan Wojcicki, CEO of YouTube, died from non-small-cell lung cancer in 2024. An avid runner, she wasn’t diagnosed until she went to a doctor for hip pain. After she underwent an MRI, her doctors discovered not only that she had lung cancer, but that it had spread.
For He, the low-hanging fruit is avoiding death by preventable disease. The top five killers of Americans are heart disease, cancer, accidents, stroke, and chronic lower respiratory diseases, which together caused nearly 60 percent of deaths in 2025. Catch or delay those issues long enough, He reasons, and you easily gain a couple of decades. But the real goal, He says, is “healthspan” extension. Nobody wants to live past 100 if those final years won’t be spent with a sharp mind and a healthy body.
That’s why he was intrigued when, around 2013, his old boss Venter told him he was co-founding a new company called Human Longevity. Venter explained that the company would use post-genome technology and phenotype data to help people live longer and healthier. Sold on the vision, He invested $40 million in the Series B, which put him on the board. Antibiotics and vaccines have been some of the biggest movers in human life expectancy, helping bring the average lifespan from about 30 to nearly 80 in developed nations over the last 200 years. A simple HPV vaccination could have saved He’s grandmother from cervical cancer. Genome sequencing and early detection, He thought, could be that next huge leap in human lifespan.
A year in, though, Human Longevity nearly ran out of investors. He was the only one willing to sink more money into such a big bet, and in 2019, he became the company’s executive chairman and CEO — and decided that Human Longevity would be his full-time passion project.
What Human Longevity sells today is a deep look inside the body. For $8,000, clients receive a comprehensive executive health package: four to five hours in the office for whole-genome sequencing, a whole-body MRI, cardiac imaging, and hundreds of biomarker tests. Human Longevity’s $12,000 and $19,000 packages offer additional tests, such as cancer liquid biopsies. Customers leave owning their own data — about 150 gigabytes of it, hosted on Human Longevity’s servers. In May 2026, the company announced that it would offer whole-genome sequencing for $599 — a price point that He says democratizes access and has the potential to improve health management for billions of people.
As He views it, Human Longevity has a few major competitive advantages, even in an ever more crowded space. The first is that the team treats tests like a symphony — an array of exams interpreted in concert, which is more powerful than considering any result in isolation. Second, Human Longevity has been collecting longitudinal data on the same clients for 10 to 15 years, which the company says improves its ability to analyze health and predict outcomes. In contrast, new entrants to the space only have access to public data. Finally, Human Longevity offers a $1 million cancer guarantee. If adhered to correctly, He says, his service makes missing late-stage cancer impossible — and if a member’s cancer happens to slip through the cracks, Human Longevity promises to commit $1 million to treatment.
Of course, in life, there are no guarantees. Some doctors suggest that “over-testing” may lead patients to seek aggressive treatment for conditions that don’t warrant those interventions. And will proactive testing actually lead to longer lives? For their part, the Human Longevity team is building long-term datasets to quantify whether the approach measurably improves longevity. Seeing as the average age of its members is 53, finding such proof could take several decades. Plus, members won’t live longer unless they follow up with recommendations on diet, sleep, exercise, stress reduction, and social connections. But for some, regular testing has already proven critical.
Earlier this year, Venter succumbed to a fate akin to those of Jobs and Wojcicki: Proactive testing through Human Longevity helped discover aggressive prostate cancer in 2016, and he had the organ surgically removed. Years later, though, he deviated from protocol and delayed a whole-body MRI for some 14 months. “By the time he came back, we found the tumor — it was already in his liver,” He says.
He sees Venter’s death as a cautionary tale about follow-up, not a failure of Human Longevity’s offerings. And He has approached his own health differently, becoming his own proof of concept. After getting tested, He learned that he had elevated blood sugar, was high in liver and visceral fat, was pre-diabetic, and was at risk for stroke. This was a big wakeup call: His mother had diabetes, and his father died at 88 from a stroke. After seeing his data, He lost weight, worked to reduce his cardiovascular age by 10 years, and began avoiding foods that he knows he can’t tolerate according to his genetic profile, including lactose and histamine-rich foods. He takes medication based on his genetics as well, which has helped him lower his LDL, and he wears a continuous blood glucose monitor to keep an eye on his blood sugar. “There are a few things I can’t change — I like steak,” he says with a smile. “I would rather die three years younger and not miss my steak.” But small joys in moderation — like a good meal or a glass of wine — are a part of Zheng’s second pillar of longevity. He makes sure to take time when he can to play golf and enjoy dinners with his wife and five children.
Though programs like Human Longevity can delay or thwart disease, science hasn’t yet found a way to slow the aging process. Could we someday get to the age of 110 or even 120, He wonders? Maybe.
He thinks about the problem holistically — and believes that more research is needed on the aging process and how both society and businesses support individuals as they live longer. With this in mind, he has funded programs like the Wharton HEALS Initiative, which bridges the School’s business expertise with clinical and scientific advancements. “That interdisciplinarity means that we analyze problems, conduct research, and develop solutions that are multi-dimensional, helpful for population health, and sustainable business-wise,” says Ingrid Nembhard, co-director of HEALS and chair of the health care management department.
He gifted the inaugural donation to HEALS through the Huiying Memorial Foundation, a nonprofit named for his beloved grandmother. That funding has allowed HEALS to launch new longevity studies. But Guy David, the initiative’s co-director, insists that He’s “interest in being involved and his thought leadership around longevity are far more important than the money.” He has lent ideas, expertise, and connections, David says: “He’s quite a visionary. He also goes 100 miles an hour with his ideas. It’s phenomenal to interact with him.”
Where will Human Longevity take things next? AI is the big unlock, according to He. Having your genome sequenced is nice, but it’s the interpretation that matters most. “If I just decode your genome, that’s useless on its own,” He says. “It’s like handing you a Bible written in Hebrew. If you don’t read Hebrew, you won’t get any understanding from it. The real job — interpreting the Bible — is what Human Longevity is doing.” Human Longevity now offers an AI-driven app for clients: a proprietary chat agent loaded with terabytes of client data. Want to take a new medication? Ask the app if it will work well for your genomic type. Wondering about your top disease risks? The app can tell you that too.
He is still chasing the life Zheng modeled for him, particularly his mentor’s refusal to treat any limit as fixed. And He is writing a biography of Zheng, hoping to bring his story to more people. “Whenever there’s a problem, there’s always 10,000 solutions,” He says. Death is simply the largest problem on his list.
Lexi Pandell is a writer from Oakland, California, whose work has appeared in Wired and The Atlantic, among other publications. Her memoir, Holy Mother!, will be published in the fall of 2027.
Published as “Dr. He and the Quest for Longer, Healthier Lives” in the Fall/Winter 2026 issue of Wharton Magazine.

